|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL55 |
Gene summary for MRPL55 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL55 | Gene ID | 128308 |
| Gene name | mitochondrial ribosomal protein L55 | |
| Gene Alias | AAVG5835 | |
| Cytomap | 1q42.13 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | A0A024R3R0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128308 | MRPL55 | GSM4909281 | Human | Breast | IDC | 5.11e-09 | 3.79e-01 | 0.21 |
| 128308 | MRPL55 | GSM4909282 | Human | Breast | IDC | 1.12e-05 | 4.02e-01 | -0.0288 |
| 128308 | MRPL55 | GSM4909285 | Human | Breast | IDC | 4.09e-04 | 1.89e-01 | 0.21 |
| 128308 | MRPL55 | GSM4909286 | Human | Breast | IDC | 2.65e-06 | 2.71e-01 | 0.1081 |
| 128308 | MRPL55 | GSM4909287 | Human | Breast | IDC | 2.12e-02 | 2.42e-01 | 0.2057 |
| 128308 | MRPL55 | GSM4909288 | Human | Breast | IDC | 3.70e-05 | 2.85e-02 | 0.0988 |
| 128308 | MRPL55 | GSM4909290 | Human | Breast | IDC | 6.03e-08 | 4.02e-01 | 0.2096 |
| 128308 | MRPL55 | GSM4909291 | Human | Breast | IDC | 1.89e-04 | 2.96e-01 | 0.1753 |
| 128308 | MRPL55 | GSM4909293 | Human | Breast | IDC | 4.89e-17 | 4.14e-01 | 0.1581 |
| 128308 | MRPL55 | GSM4909296 | Human | Breast | IDC | 5.41e-07 | 2.23e-01 | 0.1524 |
| 128308 | MRPL55 | GSM4909297 | Human | Breast | IDC | 2.47e-08 | 2.09e-02 | 0.1517 |
| 128308 | MRPL55 | GSM4909298 | Human | Breast | IDC | 2.69e-13 | 4.15e-01 | 0.1551 |
| 128308 | MRPL55 | GSM4909301 | Human | Breast | IDC | 6.82e-12 | 4.73e-01 | 0.1577 |
| 128308 | MRPL55 | GSM4909302 | Human | Breast | IDC | 1.78e-07 | 3.45e-01 | 0.1545 |
| 128308 | MRPL55 | GSM4909306 | Human | Breast | IDC | 6.05e-19 | 5.62e-01 | 0.1564 |
| 128308 | MRPL55 | GSM4909307 | Human | Breast | IDC | 1.14e-15 | 5.33e-01 | 0.1569 |
| 128308 | MRPL55 | GSM4909308 | Human | Breast | IDC | 1.36e-33 | 6.87e-01 | 0.158 |
| 128308 | MRPL55 | GSM4909309 | Human | Breast | IDC | 7.27e-05 | 2.61e-01 | 0.0483 |
| 128308 | MRPL55 | GSM4909311 | Human | Breast | IDC | 2.16e-18 | -1.28e-02 | 0.1534 |
| 128308 | MRPL55 | GSM4909312 | Human | Breast | IDC | 4.18e-09 | 1.19e-01 | 0.1552 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL55 | SNV | Missense_Mutation | novel | c.163A>G | p.Thr55Ala | p.T55A | Q7Z7F7 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | novel | c.109T>C | p.Cys37Arg | p.C37R | Q7Z7F7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.136) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | rs758299560 | c.460N>T | p.Arg154Cys | p.R154C | Q7Z7F7 | protein_coding | deleterious(0) | possibly_damaging(0.804) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| MRPL55 | SNV | Missense_Mutation | c.187C>T | p.His63Tyr | p.H63Y | Q7Z7F7 | protein_coding | tolerated(0.06) | benign(0.135) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| MRPL55 | SNV | Missense_Mutation | rs376021962 | c.377N>A | p.Arg126Gln | p.R126Q | Q7Z7F7 | protein_coding | tolerated(0.1) | possibly_damaging(0.873) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | novel | c.451C>T | p.His151Tyr | p.H151Y | Q7Z7F7 | protein_coding | deleterious(0.03) | benign(0.182) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | rs766879446 | c.166G>A | p.Gly56Arg | p.G56R | Q7Z7F7 | protein_coding | tolerated(0.31) | benign(0.114) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| MRPL55 | SNV | Missense_Mutation | novel | c.455T>C | p.Val152Ala | p.V152A | Q7Z7F7 | protein_coding | tolerated(0.52) | benign(0.051) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | rs751426782 | c.394C>T | p.Arg132Cys | p.R132C | Q7Z7F7 | protein_coding | deleterious(0.02) | benign(0.267) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL55 | SNV | Missense_Mutation | novel | c.365C>A | p.Pro122His | p.P122H | Q7Z7F7 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |